Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects' parent(s)/ Legally Acceptable Representative (s) \[LAR(s)\] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.~* Written informed consent obtained from the parent(s)/ LAR(s) of the subject prior to performing any study specific procedure.~* A male or female between, and including, 6 and 10 weeks of age at the time of the first vaccination.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Birth weight \>2000 grams.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccine (Day-29 to Day 1), or planned use during the study period.~* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.~* Administration of any chronic drug therapy to be continued during the study period.~* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose of vaccine administration and ending at Visit 3; with the exception of the inactivated influenza vaccine, which is allowed at any time during the study, and other licensed routine childhood vaccinations, according to the local immunization practice.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* History of confirmed RV GE.~* Previous vaccination against RV.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, (including Severe Combined Immunodeficiency \[SCID\] disorder) based on medical history and physical examination.~* Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS).~* History of IS.~* Very prematurely born infants (born ≤28 weeks of gestation).~* Hypersensitivity to latex.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurological disorders or seizures.~* Acute disease and/or fever at the time of enrolment. This warrants deferral of vaccination.~  * Fever is defined as temperature ≥38.0°C/100.4°F. The preferred location for measuring temperature in this study will be the oral cavity, the axilla or the rectum.~ * Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or medical history.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).~* GE within 7 days preceding the study vaccine administration (warrants deferral of the vaccination).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Study Arms:
- HRV Liq Group (Type: EXPERIMENTAL): Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
- HRV Lyo Group (Type: ACTIVE_COMPARATOR): Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete